Project Grant R37CA307597
Award Date 6/9/26
Completion Date 5/31/31
Dollars Obligated $374K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded a $501,803 Project Grant to The University of Texas Southwestern Medical Center (UT Southwestern) effective June 1, 2026, through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports fundamental and applied laboratory research focused on decoding the stromal microenvironment of pancreatic ductal adenocarcinoma (PDAC), specifically examining the role of antigen-presenting...
- Federal Grant Award Summary The National Cancer Institute awarded a $141,195 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The University of Texas MD Anderson Cancer Center on May 15, 2026, with completion expected by April 30, 2028. This award supports a Pathway to Independence (K99/R00) career development research project investigating how tumor suppressor gene (TSG) deficiencies modulate pancreatic ductal adenocarcinoma (PDAC) response to oncogenic KRAS...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $168,000 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded April 1, 2026, with completion scheduled for March 31, 2028. This research initiative focuses on understanding and targeting dormancy mechanisms in pancreatic ductal adenocarcinoma (PDAC) to improve patient survival outcomes. The project investigates minimal residual dormant disease (MRD)...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $510,671 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded May 1, 2026, with a completion date of April 30, 2031. This five-year research initiative focuses on functionally characterizing the lineage plasticity landscape of cholangiocarcinoma (CCA), a highly lethal bile duct cancer. The project will deliver comprehensive research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $706,739 Project Grant to The University of Texas MD Anderson Cancer Center on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the molecular mechanisms of immunotherapy-associated myocarditis. This five-year research initiative (through May 31, 2031) addresses a critical clinical challenge: immune checkpoint inhibitor (ICI) treatments, while effective in cancer therapy, can trigger...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $669,540 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. This five-year research initiative investigates the role of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy in KRAS-mutant lung adenocarcinomas (KM-LUADs). The research builds on...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $166,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2028. The award supports research titled "Targeting Cell Death Pathways to Prevent KRAS Inhibitor Resistance," which investigates mechanisms to overcome therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC)....
- Federal Grant Award Summary The National Cancer Institute awarded a $150,404 Project Grant to The University of Texas MD Anderson Cancer Center, effective December 1, 2025, through May 31, 2028, under the Cancer Research Manpower program (CFDA 93.398). This award supports a research project titled "Dissecting the Role of Gut Microbiome Dysbiosis in Lung Cancer Development and Progression," which investigates the mechanistic relationship between gut microbiome composition and lung...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $683,970 Project Grant to Columbia University's Health Sciences Division effective April 1, 2026 through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project focuses on developing and evaluating therapeutic approaches to treat pancreatic ductal adenocarcinoma (PDAC) through stromal modification and immune modulation. The research investigates the role of αvβ5 integrin in PDAC...
- Federal Project Grant Award Summary Columbia University's Health Sciences Division, in receipt of a $109,080 Project Grant awarded September 1, 2025, by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), is conducting a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The trial compares a four-drug regimen...